Skip to main content
. 2023 Jun 29;12(13):e029071. doi: 10.1161/JAHA.122.029071

Figure 3. Proportion of patients per drug type.

Figure 3

ACEi indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi, angiotensin receptor–neprilysin inhibitor; MRA, mineralocorticoid receptor antagonist; and SGLT2I, sodium‐glucose cotransporter 2 inhibitor.